Objectives: This study aims to determine the prevalence and factors associated with unrounded doses ordered via a computerized prescriber order entry (CPOE) system among children during a 1-week reference period.

Methods: This retrospective, cross-sectional study included children younger than 18 years admitted during a 7-day period. An unrounded dose was defined as an unrounded actual dose (eg, dose calculated to the tenths place for non-neonatal intensive care (non-NICU) patients and dose calculated to the hundredth place for NICU patients) or unrounded volume per dose [eg, <0.1 mL for non-NICU patients and <0.01 mL for NICU patients]. A multilevel logistic regression model was used to determine the prevalence and factors associated with unrounded doses via a CPOE system with adjustment for clustering effects.

Results: A total of 395 patients were admitted with 391 receiving medications. The overall prevalence of unrounded doses was 30% among the 2426 doses administered. Patients on the NICU team had the highest prevalence of unrounded doses. The odds of an unrounded dose were 4% (adjusted odds ratio, 0.96; 95% confidence interval, 0.94-0.98) lower with each additional kilogram increase in weight after controlling for age, route, scheduled versus as-needed administration, and cluster effects.

Conclusions: The prevalence of unrounded doses was higher than in previous studies. It was higher in smaller children after controlling for age, medication-related variables, and clustering. Future studies should focus on the role of CPOE in preventing unrounded and unmeasurable doses and if these strategies affect clinical outcomes (eg, adverse drug events).

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5562209PMC
http://dx.doi.org/10.5863/1551-6776-22.4.286DOI Listing

Publication Analysis

Top Keywords

dose calculated
8
dose
5
prevalence unrounded
4
unrounded medication
4
medication doses
4
doses associated
4
associated factors
4
factors hospitalized
4
hospitalized pediatric
4
pediatric patients
4

Similar Publications

This paper introduces a class of insulin-glucose-glucocorticoid impulsive systems in the treatment of patients with diabetes to consider the effect of glucocorticoids. The existence and uniqueness of the positive periodic solution of the impulsive model at double fixed time is confirmed for type 1 diabetes mellitus (T1DM) using the [Formula: see text] function. Further, the global asymptotic stability of the positive periodic solution is achieved following Floquet multiplier theory and comparison principle.

View Article and Find Full Text PDF

Background: Excessive submental fat under the chin is a known aesthetic concern because of its negative impact on facial appearance and psychological well-being. AYP-101 is a newly developed injectable agent containing 93% soybean phosphatidylcholine (SPC) designed to reduce submental fat. We conducted a phase 1 study to evaluate the safety, pharmacokinetic (PK), and lipid profile effects of AYP-101.

View Article and Find Full Text PDF

Background: Multidose iodinated contrast media (ICM) injectors have shown promise in reducing ICM waste. This study aims to evaluate the impact of patient volume on ICM waste reduction in multidose injectors.

Methods: CT studies performed over one-year period with a multidose injector at our emergency CT unit.

View Article and Find Full Text PDF

Persistence, severity and reactivity thresholds in fish allergic patients sensitized to parvalbumin.

J Allergy Clin Immunol Pract

December 2024

Servicio de Alergia, Hospital Clínico San Carlos, IdISSC, Madrid, Spain; Facultad de Medicina, Universidad Complutense, Madrid, Spain. Electronic address:

Background: Fish allergy affects children and adults worldwide and there are transient and persistent phenotypes.

Objective: We aimed to analyze persistence, severity and reactivity thresholds in challenge-confirmed fish allergic patients sensitized to parvalbumin.

Methods: Patients 12-65 years-old reporting immediate reactions to fish, with fish skin prick test ≥5 mm and IgE to cod and carp β-parvalbumins ≥0.

View Article and Find Full Text PDF

Objectives: Chronic myeloid leukemia (CML) management now includes dose-reduction (DR) and treatment-free remission (TFR). Evaluating cost-effectiveness of lifelong-prescribed expensive tyrosine kinase inhibitors (TKIs) for CML is crucial. Prior cost-effectiveness evaluations state that imatinib is the favorable frontline TKI.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!